

Patent Attorney Docket No. 16867-2US MG/pd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: François AUGER et al.

SERIAL NO.: 10/511,433

Group Art Unit: 1644

FILED:

March 15, 2005

FOR:

METHOD FOR PREPARING TISSUE CONSTRUCTS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT **FEE REQUIRED**

Sir or Madam:

Pursuant to the duty of disclosure under 37 CFR 1.56, copies of the references listed on the attached PTO Form SB/08A/B are submitted herewith.

The Commissioner is hereby authorized to charge the fee of \$180.00, required for late submission of this Information Disclosure Statement in accordance with 37 CFR 1.97(c), to Deposit Account Number 19-5113. The Commissioner is further authorized to charge any fees which may be required, or credit any overpayment to the Deposit Account # 19-5113.

In accordance with 37 CFR 1.97(h), the submission of the present information is not to be construed as an admission that such information is, or is considered to be material to patentability.

06/17/2005 JBALINAN 00000071 195113 10511433

01 FC:1806

180.00 DA

The Examiner is kindly requested to consider these references during the examination of the above-identified application, making the references of record, and to return an initialed copy of the Form SB/08A/B to the undersigned agent.

Respectfully submitted,

François Auger et al.

By:

Isabelle Chabot
Patent Agent
Registration No. 55,764
OGILVY RENAULT, LLP
Customer No. 020988

1981 McGill College Avenue, Ste 1600 Montreal, Quebec, Canada H3A 2Y3

Chabelle Chabat

Tel.: (418) 640-5174

Encls: Copies of references Form PTO/SB/08A/B

PTO/SB/08A/B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Parawork Reduction Action 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute & TOTAL And B/PTO				Complete if Known		
				Application Number	10/511,433	
INF	ORMATIO	N DISC	LOSURE	Filing Date	15 mars 2005	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	François A. Auger et al.	
				Art Unit	1644	
	(use as many sh	eets as nece	ssary)	Examiner Name	·	
Sheet	1	of	2	Attorney Docket Number	16867-2US	

U.S. PATENT DOCUMENTS					
Examiner Initiats*	Cite No.1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US 5,763,275	06/09/1998	Nagels et al.	
		US 5,710,043	01/20/1998	Nicholas George Martin Pay	
		US 5,610,007	03/11/1997	Auger et al.	
		US 5,316,945	05/31/1994	Minuth	
		US 5,665,596	09/09/1997	Mussi	·
		US 5,693,537	12/02/1997	Wilson, et al.	
		US 5,665,599	09/09/1997	Minuth	
		US 5,618,718	04/08/1997	Auger et al.	
		US 20010014475 A1	08/16/2001	Frondoza et al.	
		US 5,955,343	09/21/1999	Holmes et al.	
		US 5,670,483	09/23/1997	Zhang et al.	
		US 5,710,049	01/20/1998	Noppe et al.	
		US 5,453,2780	09/26/1995	Chan et al.	
		US 6,133,030	10/17/2000	Bhatia et al.	
		US 5,750,329	05/12/1998	Quinn et al.	
			10 40 10		
	l		+		
			1		
		· ·	1		
		<u></u>		1	

FOREIGN PATENT DOCUMENTS							
Examiner Cite No.1		Foreign Patent Document Country Code3 – Number4 – Kind Code5 (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant Of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Τ*	
		EP 1 077 072 A2	02/21/2001	Hoerstrup et al.			
		WO 0029553	02/25/2000	Murphy et al.			
		WO 9948541	09/30/1999	Weiss et al.		\Box	
		WO 00/66036	11/09/2000	Vacanti et al.		\top	
		WO 99/01538	01/14/1999	Niklason et al.		F	
						-	
		•					

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reductor Act of 1995, no present are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A			C	Complete if Known		
			Application Number	10/511,433		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	15 mars 2005		
			First Named Inventor	François A. Auger et al.		
			Art Unit	1644		
(use as many sheets as necessary)		Examiner Name				
Sheet	2	16	Attorney Docket Number	16867-2US		

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examin er Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		CAPPADONA ET AL., «Phenotype Dictates the Growth Response of Vascular Smooth Muscle Cells to Pulse Pressure in Vitro", Experimental Cell Research , 1999, pages 174-186, 250	
		L'HEUREUX ET AL. "A completely biological tissue-engineered human blood vessel", The FASEB Journal, 1998, Pages 47-57 Vol. 12,	
		HATA ET AL., "L-Ascorbic Acid 2-Phosphate Stimulates Collagen Accumulation, Cell Proliferation, and Formation of a Three-Dimensional Tissulike Substance by Skin Fibroblasts", Journal of Cellular Physiology, 1989. Pages 8-16, vol. 138	
		PETERKOFSKY, "the Effect of Ascorbic Acid on Collagen Polypeptide Synthesis and Proline Hydroxylation During the Growth fo Cultured Fibroblasts", Archives of Biochemistry and Biophysics, 1972, pages 318-328, vol. 152	
		GEESIN ET AL., "Ascorbic Acid Specifically Increase Type I and Type III Procollagen Messenger RNA Levels in Human Skin Fibroblasts", Journal of Investigative Dermatology, 1988 pages 420-424, vol. 90	
		MICHEL ET AL., "Characterization of a New Tissue-Engineered Human Skin Equivalent With Hair", In Vitro Cellular and Developmental Biology. Animal, 1999, pages 318-326, vol. 35	
		L'Heureux et al, 2001, «A human tissue-engineered vascular media : a new model for pharmacological studies of contractile responses » FASEB Journal, 15, 515-525	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.